Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Biovitrum AB acquires the pharmaceutical company Arexis AB
Mandate

Biovitrum AB acquires the pharmaceutical company Arexis AB

October 03, 2005

Biovitrum, a Swedish biotech company, acquires Arexis, a privately owned Swedish biotech and pharmaceuticals company, for an undisclosed consideration, from 3i Group Plc, Beijer Investors, Industrifonden, InnovationsKapital, and SEB Företagsinvest.

Vinge acted for Biovitrum AB.
Michael Wigge (responsible partner)
Niclas Bergström (associate)

Related

Vinge has advised Axcel VI and Currentum in connection with the acquisition of Klarins Rör

 Vinge has advised Axcel VI and the Currentum Group in connection with the acquisition of Klarins Rör i Göteborg AB (“Klarins Rör”).
December 09, 2025

Vinge advises on the sale of RK Projektledning to Qflow

 Vinge has advised the sellers in connection with the sale of all shares in RK Projektledning AB to Qflow Group.
December 05, 2025

Vinge represents IKEA Forestry Investment AB in connection with the acquisition of forest land in Latvia and Lithuania

 Vinge assists IKEA Forestry Investment AB (a company within the Inter IKEA group) in the acquisition of a Latvian and a Lithuanian company from Dasos Timberland Fund II (a fund managed by CapMan Natural Capital).
December 05, 2025